. 2021 Jun 30;16(6):e0253336. doi: 10.1371/journal.pone.0253336

Table 1. Number and period prevalence of persons with and without anticholinergic burden measured through the Anticholinergic Cognitive Burden (ACB) scale during the observation period (2016), by sex and age.

		ACB score
	Total	ACB = 0		ACB = 1		ACB = 2		ACB ≥ 3
Sex	N^a	N^b	Prevalence (%)	N^b	Prevalence (%)	N^b	Prevalence (%)	N^b	Prevalence (%)
Men	7,635,507	5,232,064	68.5	1,342,836	17.6	507,767	6.7	552,840	7.2
Age
≤ 18	1,361,884	1,069,419	78.5	185,882	13.6	30,520	2.2	76,063	5.6
19 to 29	1,128,700	956,617	84.8	121,521	10.8	31,648	2.8	18,914	1.7
30 to 39	1,077,901	862,425	80.0	138,917	12.9	44,353	4.1	32,206	3.0
40 to 49	975,152	715,119	73.3	158,347	16.2	55,720	5.7	45,966	4.7
50 to 59	1,210,955	790,562	65.3	240,566	19.9	92,866	7.7	86,961	7.2
60 to 69	853,986	448,660	52.5	214,327	25.1	96,021	11.2	94,978	11.1
70 to 79	697,604	285,943	41.0	191,496	27.5	100,439	14.4	119,726	17.2
80 to 89	293,902	93,090	31.7	82,108	27.9	49,783	16.9	68,921	23.5
90 to 99	35,049	10,119	28.9	9,557	27.3	6,353	18.1	9,020	25.7
≥ 100	374	110	29.4	115	30.7	64	17.1	85	22.7
Women	8,835,439	5,447,201	61.7	1,741,731	19.7	728,329	8.2	918,178	10.4
Age
≤ 18	1,286,334	1,017,119	79.1	167,010	13.0	28,592	2.2	73,613	5.7
19 to 29	1,120,182	867,427	77.4	175,136	15.6	47,879	4.3	29,740	2.7
30 to 39	1,154,740	850,292	73.6	194,824	16.9	62,185	5.4	47,439	4.1
40 to 49	1,214,399	804,947	66.3	236,844	19.5	87,472	7.2	85,136	7.0
50 to 59	1,516,942	888,755	58.6	329,169	21.7	138,788	9.1	160,230	10.6
60 to 69	1,086,934	531,914	48.9	264,899	24.4	128,807	11.9	161,314	14.8
70 to 79	923,303	344,264	37.3	238,524	25.8	138,632	15.0	201,883	21.9
80 to 89	429,269	117,652	27.4	109,445	25.5	76,061	17.7	126,111	29.4
90 to 99	100,998	24,229	24.0	25,221	25.0	19,451	19.3	32,097	31.8
≥ 100	2,338	602	25.7	659	28.2	462	19.8	615	26.3

^a Denominator of the prevalence are persons insured for ≥1 day within the observation period and with ≥1 year continuous insurance before.

^b Numerator of the prevalence, calculated as the number of persons with ACB = 0, ACB = 1, ACB = 2, and ACB ≥ 3, respectively. Persons will be allocated in the highest level of the ACB score ever reached during the observation period.